Rebus Holdings, Inc. (RBSH)

OTCMKTS: RBSH · Delayed Price · USD
-0.0007 (-87.50%)
Jul 16, 2024, 9:30 AM EDT - Market open
Market Cap 3.21K
Revenue (ttm) n/a
Net Income (ttm) 1.53M
Shares Out 32.13M
EPS (ttm) 0.03
PE Ratio 0.00
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 334
Open 0.0001
Previous Close 0.0008
Day's Range n/a
52-Week Range 0.0001 - 0.0149
Beta 1.67
Analysts n/a
Price Target n/a
Earnings Date n/a

About RBSH

Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol RBSH
Full Company Profile

Financial Performance

Financial Statements


Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline

Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 20...

3 years ago - Accesswire